Date | Dividend Per Share | Free Cash Flow Per Share | Return on Assets (ROA) | Return on Equity (ROE) |
---|
CEO | Mr. Johan Waborg |
IPO Date | April 6, 2018 |
Location | Sweden |
Headquarters | Medicon Village |
Employees | 28 |
Sector | Healthcare |
Industries |
Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler, as well as provides customized inhalation solutions. It serves generic companies. The company has an agreement with Immune System Regulation AB for the development of an inhaled covid-19 vaccine in Iconovo's inhaler ICOone; and Respiratorius AB (publ) to develop inhalation product to treat COPD. Iconovo AB (publ) was founded in 2013 and is based in Lund, Sweden.
Past 5 years
USD 2.87
USD 3.06
USD 30.85
USD 20.58
USD 2.27
StockViz Staff
February 4, 2025
Any question? Send us an email